Nature discusses the first application of CRISPR technology to humans. It was in China. They state:
On 28 October, a team led by oncologist Lu You at Sichuan University
in Chengdu delivered the modified cells into a patient with aggressive
lung cancer as part of a clinical trial at the West China Hospital, also in Chengdu. Earlier clinical trials using cells edited with a different technique
have excited clinicians. The introduction of CRISPR, which is simpler
and more efficient than other techniques, will probably accelerate the race to get gene-edited cells into the clinic
across the world, says Carl June, who specializes in immunotherapy at
the University of Pennsylvania in Philadelphia and led one of the
earlier studies....June is the scientific adviser for a planned US trial
that will use CRISPR to target three genes in participants’ cells, with
the goal of treating various cancers. He expects the trial to start in
early 2017. And in March 2017, a group at Peking University in Beijing
hopes to start three clinical trials using CRISPR against bladder, prostate and renal-cell cancers. Those trials do not yet have approval or funding.
They note that this may become a race comparable to the space race of the 1960s. We have been following this for about three years now and the potential is significant but CRISPR Cas 9 still has the DSB problem of reassembly as well as the targeting specificity.